Published in final edited form as:

Biomarkers. 2010 December ; 15(8): 663–670. doi:10.3109/1354750X.2010.509811.

Alkaline Phosphatase and Percent Body Fat Predict Circulating C-Reactive Protein in Premenopausal Women¹

Fatima Nayeem, Ph.D.^{*}, Karl E. Anderson, M.D.^{*}, Manubai Nagamani, M.D.^{**}, James J. Grady, Dr. P.H.^{*}, and Lee-Jane W. Lu, Ph.D.^{*,2}

^{*}Department of Preventive Medicine and Community Health, the University of Texas Medical Branch, Galveston, TX 77555-1109

^{**}Department of Obstetrics and Gynecology, the University of Texas Medical Branch, Galveston, TX 77555-1109

Abstract

C-reactive protein (CRP) is considered a marker of inflammation, which is a risk factor for many chronic diseases. However, determinants of CRP remain unclear and were studied in a strictly defined cohort of healthy premenopausal women (n=233) using multiple regression models. Independent predictors of serum CRP (model R²=0.59) were percent body fat, serum alkaline phosphatase (ALP), sex hormone binding globulin (SHBG), and white blood cell (WBC) count. The close association between CRP and ALP suggests that enzymatic activity of ALP may be important for the anti-inflammatory effects of CRP, which should be confirmed with additional studies.

Keywords

Obesity; SHBG; Insulin; Liver enzymes; White blood cells

Introduction

Chronic low-grade inflammation that is associated with obesity is considered to influence development of the metabolic syndrome, type 2 diabetes, cardiovascular disease (Hotamisligil, 2006), and various malignancies (Coussens and Werb, 2002). In response to inflammation and infection, the liver increases synthesis of many acute phase reactant proteins, including C-reactive protein (CRP)³. CRP was discovered as an acute phase reactant in humans by Tillet and Francis in 1930 (Tillet and Francis, 1930). It belongs to the phylogenetically ancient and highly conserved family of pentraxins. Circulating levels of CRP increase dramatically in response to infection and other inflammatory processes (Black et al., 2004). CRP is believed

¹Research Supported by U.S. Army Medical Research and Materiel Command DADM17-01-1-0417 (The content of the information does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred. The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014 is the awarding and administering acquisition office.), and National Institute of Health (NIH) Grants National Center for Research Resources M01-RR-00073 and 1UL1RR029876-01, National Cancer Institute CA95545, CA65628, and National Institute of Environmental Health Sciences ES006676. The study is registered at www.clinicaltrials.gov and the identifier is NCT00204477 and the clinical trial registration date is September 9, 2005.

² **Corresponding author:** Lee-Jane W. Lu, Ph.D. at the Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, 700 Harborside Drive, Galveston, TX 77555-1109; Phone: 4097721730; Fax: 4097726287; llu@utmb.edu.

Disclosures: All authors have no financial conflict of interest.

³**Abbreviations used:** CRP, C-reactive protein; ALP, alkaline phosphatase; BMI, body mass index; WBC, white blood cells; SHBG, sex hormone binding globulin; HDL-C, high density lipoprotein-cholesterol; ALT, alanine aminotransferase; AST, aspartate aminotransferase;

to play an important role in innate immunity by binding phosphocholine (PC) on microbes and on injured or apoptotic cells, thereby initiating the process of phagocytosis by macrophages (Casey et al., 2008).

Increased CRP levels are also associated with obesity (Visser et al., 1999). CRP levels have been associated with the number of manifestations of the metabolic syndrome (Zambon et al., 2005, Florez et al., 2006) and are predictive for development of this syndrome and type 2 diabetes (Freeman et al., 2002, Ridker, 2007). CRP is therefore considered to be a potentially important predictor of cardiovascular disease risk (de Ferranti and Rifai, 2007). CRP may also increase with development of some human malignancies (McSorley et al., 2007, Polterauer et al., 2007, Gockel et al., 2006). However, although CRP has been associated with several adverse health outcomes, the independent predictors of CRP remain unclear.

Many liver proteins are routinely measured in serum to diagnose liver dysfunction. For examples, serum aspartate amino transferase (AST), alanine amino transferase (ALT), and alkaline phosphatase (ALP) are useful diagnostic markers for liver diseases, including nonalcoholic fatty liver disease (NAFLD), which is a clinically important manifestation of the metabolic syndrome. Serum CRP levels are also increased in NAFLD (Kerner et al., 2005, Booth et al., 2008). This is not surprising, because this is an inflammatory condition, and the synthesis of CRP occurs primarily in the liver, where it is regulated by pro-inflammatory cytokines, including, IL-1, IL-6, and TNF- α , which are produced by adipose tissue (Yudkin et al., 1999, Zhang et al., 1995). White blood cell (WBC) counts also increase in obesity and inflammatory conditions (Dixon and O'Brien, 2006) and these cells are an important source of pro-inflammatory cytokines. Thus, in response to stress, the liver makes an array of proteins including CRP, and adiposity may disturb the homeostasis of these liver proteins. Surprisingly little is known about the influence of obesity on serum levels of various proteins synthesized by the liver and their interrelationships. This was investigated in a strictly defined cohort of healthy premenopausal women from whom blood samples were obtained during the luteal phase of the menstrual cycle, in order to minimize the influences of ovulation and changing hormone levels, and to study the roles of luteal phase hormones.

Methods

Study Design

A defined group of premenopausal women (n=233), which included all major racial and ethnic groups found in the U.S. population, was studied during the luteal phase of two separate menstrual cycles. Subjects were recruited from within an 80 km radius of Galveston, Texas, using flyers and advertisements that were posted or sent by web or postal mail. The study protocol was approved by the Institutional Review Board of the University of Texas Medical Branch (UTMB) and by the Human Research Protection Office of the US Army Medical Research and Materiel Command. Written informed consents were obtained from all subjects.

Enrollment was restricted to healthy 30- to 40-year-old premenopausal women with regular menstrual cycles. The subjects were enrolled in an extended dietary intervention study of biomarkers for breast cancer risk. Exclusion criteria were: breast cancer; serious health conditions such as cardiovascular diseases; current pregnancy or breast feeding; recent use of contraceptive medications (oral, injection, or patch); and menopause. Inclusion of women with regular menstrual cycles (every 24-35 days) provided for blood collection during the luteal phase of the cycle, when progesterone levels are increased. This allowed us to study associations with levels of both 17 β -estradiol and progesterone. Three study visits were scheduled during the luteal phase of two separate menstrual cycles (a total of 6 visits), usually between cycle days 20 and 24. The samples collected during the baseline visits of these subjects

were the source for these analyses. In order to exclude effects of acute inflammation, study visits were rescheduled if a subject reported a concurrent acute illness or infection.

Anthropometrics, body composition, and reproductive factors

At each study visit, body weight and height, waist circumference at the umbilicus and hip circumference at the widest point around the buttocks were measured. At one study visit, total, lean, and fat body mass were measured in duplicate (before and after repositioning) with the subject supine, by dual energy x-ray absorptiometry (DXA) (Model Discovery A; Model QDR4500A, Hologic, Waltham, MA). Coefficients of variation (CV) for the two readings of body composition by DXA were <5% and the mean of the two measurements was used for statistical analyses. Reproductive and general health histories were obtained once using a self-administered standard clinic questionnaire.

Hormone assays and blood chemistries

Fasting (~12 h) venous blood samples were drawn between 8:00 and 10:00 a.m. on all study visits. Aliquots of serum and plasma were stored at -80°C until analyzed. Due to limited resources, three plasma samples (all from one menstrual cycle) were analyzed in duplicate for 17 β -estradiol, testosterone, and progesterone. A radioactive immunoassay (RIA) kit was used to measure plasma progesterone concentrations (sensitivity, 0.1 ng/ml). ELISA kits were used for measuring plasma testosterone concentrations (sensitivity, 0.04 ng/ml) and plasma 17 β -estradiol concentrations (sensitivity, 7 pg/ml). Serum samples from the first and fifth study visits were assayed for CRP (sensitivity, 0.0016 mg/L) by a high sensitivity ELISA, and for sex hormone binding globulin (SHBG) (sensitivity, 0.61 nmol/L) by ELISA, and for insulin by direct RIA (sensitivity, 1.3 μ IU/ml). All immunoassays were performed using commercially available kits (Diagnostic System Laboratories, Inc. Webster, TX). All hormone measurements were in duplicate. Duplicate serum concentrations were used to determine intra-assay CV. Quality controls (low and high level) provided with the kits were run with each assay and these levels were used to determine inter-assay CV ($n > 30$). The intra- and inter-assay CV for all analytes were <10%.

Fasting serum glucose, total and high-density lipoprotein cholesterol (HDL-C), triglycerides, albumin, ALT, AST, and ALP were measured in serum samples from the first and sixth study visits by a certified hospital clinical laboratory using VITROS® 5.1 FS (Ortho-Clinical Diagnostics, Rochester, NY). White blood cell counts in blood samples from the first and sixth study visits were obtained with an automated Sysmex, HST-N system (Sysmex America Inc. Mundelein, IL).

Statistical analyses

Data are presented as means and standard deviations (SD) for continuous variables and as frequencies for categorical variables. The distributions of concentrations of serum proteins, hormones, and enzymes were checked for normality. Values of CRP, ALT, and AST were log-transformed prior to statistical analyses due to skewed distribution. The distribution of CRP, ALT, and AST among the study subjects is reported in raw form. Pearson's correlation coefficients were estimated to assess the linear relationship between log CRP, ALP, and the predictor variables. Ethnicity and parity were treated as categorical variables. Subjects were divided into three groups: normal weight, overweight, and obese, according to World Health Organization (WHO) guidelines (2000), and multiple comparisons across groups were made using the MULTTEST Procedure in SAS®.

The outcome variables for this study were serum CRP, ALP, and various measures of adiposity. Means of two measurements of serum CRP, SHBG, lipids, and liver enzymes, and blood WBC count, using samples that were collected from each woman at least one month apart, were the

predictor variables. Means of three measurements of steroid hormones, 17 β -estradiol, testosterone, and progesterone (all from one menstrual cycle) were used in statistical analyses. Independent predictors of CRP, ALP, and various measures of adiposity were determined by multiple ordinary least square (OLS) regression analysis (REG Procedure in SAS[®], version 9.1, SAS Institute Inc. Cary, NC).

Results

Based on WHO guidelines, 30% of the subjects in this study were in the healthy weight range (BMI=18.5-24.9 kg/m²), 33% were overweight (BMI=25-29.9 kg/m²), and 37% were obese (BMI $\geq$ 30) (Table 1). The ethnic composition of the study population, which was 51% non-Hispanic White, 30% Hispanic, 14 % African American, 2% Asian, 3% unspecified ethnicity, and one Native American, did not differ across the three BMI categories (Table 1). Fasting serum concentrations of glucose, triglycerides, HDL-C, albumin, ALP, CRP, SHBG, insulin, and blood WBC counts exhibited significant BMI-dependent differences. The WBC counts across the three BMI groups were all within the normal range ($3.9-10 \times 10^3/\mu\text{l}$), which is evidence against acute infection. There were no BMI-dependent differences ($P \leq 0.01$) in fasting concentrations of ALT, AST, cholesterol, 17 β -estradiol, progesterone, and testosterone.

For CRP, ALT, AST, ALP, triglycerides, glucose, HDL-C, insulin, SHBG and WBC count there were high correlations between two measurements in the same subjects at two different time points, with Pearson correlation coefficients ranging from 0.53 to 0.89 (results not shown). Therefore, for these variables, the means of two measurements at least one month apart were used for analyses of correlations between various other study variables of interest.

Pearson correlation coefficients showed that log CRP correlated strongly and positively with all anthropometric variables (r ranging from 0.29 to 0.70, all $P < 0.0001$), but negatively with height ($P = 0.001$) and age of menarche ($P = 0.02$) (Table 2). Log CRP was not associated with age in this group, which had a narrow age range (30- to 40-years). Log CRP also correlated strongly and positively with serum insulin, triglycerides, glucose, ALP, and WBC count (all $P < 0.0001$), and negatively with serum SHBG, HDL-C (both $P < 0.0001$) and albumin ($P = 0.0003$). Log ALT, log AST, cholesterol, and luteal phase estradiol, progesterone, and testosterone levels were not associated with serum CRP in these subjects.

Similar to CRP, fasting serum levels of ALP correlated with anthropometric variables, namely, body weight, BMI, fat body mass, percent body fat, waist and hip circumference ($r = 0.30 - 0.39$, all $P < 0.0001$; Table 2) and lean body mass ($P = 0.04$). Serum ALP had a weak inverse correlation with height ($P = 0.01$) and did not correlate with age. Fasting serum ALP also correlated positively with fasting serum levels of insulin, glucose, and triglycerides, and blood WBC count, and negatively with SHBG, HDL-C, and albumin (P values between 0.01 and 0.0001, Table 2). ALP was also not associated with log ALT, log AST, or luteal phase estradiol, progesterone, and testosterone in univariate analysis. Unlike CRP, ALP did not correlate with age of menarche.

Twenty-nine of 200 subjects (14.5%) were smokers. Smoking status was not available for 33 subjects. The incidence of smoking was low in our study subjects, and due to a lack of any significant differences in predictor variables between smokers and non-smokers (TTEST Procedure in SAS[®]), no adjustment was made for smoking in the final regression analysis. Alcohol intake of the study subjects, as the mean intake determined from three different food records was extremely low (2.6 ± 6.5 g/day, median intake = 0.03 g/day) and was not included in the regression analysis.

Independent Predictors of CRP, ALP, or Anthropometrics

The predictors of CRP (or ALP) were studied using multiple OLS regression models and biomarkers related to the metabolic syndrome, such as SHBG, insulin, ALP (or log CRP when ALP was the dependent variable), log ALT, log AST, glucose, triglycerides, and HDL-C, WBC count, and anthropometrics as the independent variables (Table 3). Because luteal phase estradiol, progesterone, and testosterone were not associated with log CRP or ALP in univariate and in exploratory multiple regression analyses (all $P \geq 0.10$; results not shown), final multivariate regression models did not include sex steroids as predictor variables.

For log CRP as the dependent variable, serum ALP ($\beta = 0.15$, $P = 0.003$), WBC count ($\beta = 0.15$, $P = 0.003$), and percent body fat ($\beta = 0.49$, $P < 0.0001$) were the strongest positive independent predictors of CRP, while serum SHBG ($\beta = -0.12$, $P = 0.02$) was a negative predictor of CRP. These four predictor variables could explain 59% of the variance in serum CRP levels (Table 3). HDL-C, triglycerides, insulin, log ALT, or log AST (all $P > 0.1$, Table 3), while correlated with CRP in univariate analyses, were not independent predictors of CRP. BMI, waist circumference, and body fat, but not lean body mass, could replace percent body fat as independent predictors of CRP only in the regression models omitting percent body fat as a predictor variable.

The close association between ALP and CRP suggested the need to investigate the predictors of ALP. The results of multiple OLS regression models with ALP as the dependent variable are listed in Table 3. Serum CRP was the strongest positive predictor of serum ALP ($\beta = 0.27$, $P < 0.003$), followed by serum insulin ($\beta = 0.18$, $P = 0.03$), and these two predictors could explain 25% of the variance in serum ALP concentrations. However, serum ALT, AST, SHBG, glucose, HDL-C, and triglycerides, WBC count, and body fat (and other anthropometric variables) were not independent predictors of ALP (Table 3).

Literature data suggest that ALT and AST are useful surrogate markers for obesity (Kerner et al., 2005, Booth et al., 2008). We used multiple OLS regression models to explore the predictors of all anthropometric variables, but only results for BMI, waist circumference, percent body fat, and lean body mass are included herein (Table 4). Log CRP was the strongest positive predictor of all measures of obesity (all $P < 0.0001$; β coefficients ranging from 0.39 to 0.55), followed by insulin (positive) and albumin (negative). However, serum CRP was not a predictor of lean body mass ($P = 0.26$). WBC count was an independent predictor of waist circumference ($P = 0.04$). SHBG was a negative predictor for BMI, waist circumference, and lean body mass but not for percent body fat (or total body fat, results not shown). Log ALT was a significant predictor of waist circumference and lean body mass. Log AST was a predictor of waist circumference. In contrast, ALP was not a predictor for any of the anthropometric variables. Serum CRP, together with serum insulin, SHBG, and albumin, could explain 60% of the variance in BMI. Serum CRP, together with serum insulin, SHBG, ALT, AST, albumin, and WBC count could explain 58% of the variance in waist circumference. Serum CRP, together with serum insulin and albumin could explain 55% of the variance in percent body fat.

Discussion

The primary finding of this study was that obesity, CRP and ALP were closely correlated in a defined cohort of apparently healthy, ethnically diverse 30- to 40-year old women, who were not post-menopausal and not on any exogenous estrogens and with BMIs ranging from normal to obese. Log CRP had a strong correlation with serum ALP in univariate ($r = 0.44$, Table 2) and in multivariate analyses (Table 3), and CRP was the strongest independent predictor of ALP. These observations coupled with literature reports (cited below) are consistent with a

biologically plausible hypothesis that ALP may contribute importantly to the role of CRP in innate immunity.

CRP was first identified more than 75 years ago through its calcium-dependent binding to phosphocholine (PC) groups in C-polysaccharides of the cell wall of pneumococcal bacteria. Although the crystal structure of CRP is known, its physiological and pathophysiological functions remain unclear. PC is a constituent of most biological membranes and was recently defined as the principal ligand of CRP (Marnell et al., 2005). Gram-negative bacteria express PC in a phase-dependent manner, and the binding of CRP to the PC components has been reported for a variety of such pathogens, including *Leishmania donovani*, *Hemophilus influenza*, and *Neisseria meningitidis* (Casey et al., 2008, Weiser et al., 1998). By binding to the PC component of polysaccharides, CRP opsonizes invading microbes and facilitates their uptake by macrophages and neutrophils, thus playing a key role in the innate protective response to pathogenic infections.

Alkaline phosphatases are a group of enzymes in humans and other species that hydrolyze phosphate esters at an alkaline pH (McComb et al., 1979). In healthy subjects, liver and bone are the major sources of serum ALP, but it is also present in lung, kidneys, leukocytes, intestine, and placenta (Giannini et al., 2005). Serum ALP is measured as a clinically useful marker for liver and bone disease. ALP can, at physiologic pH, remove one of the two core phosphate groups from the carbohydrate moiety of lipopolysaccharide (LPS or endotoxin) in gram-negative bacteria (Bates et al., 2007). LPS is pivotal in eliciting an inflammatory response and toxicity (Verweij et al., 2004), and the activity of ALP can render LPS nontoxic and thereby protect the host against infectious agents (Bentala et al., 2002). Therefore, it has been suggested that ALP has a role complementary to that of CRP in combating pathogens.

More recently, binding of CRP to the PC moiety of oxidized phosphatidylcholine (oxPC) on the surface of apoptotic or necrotic cells and oxidized LDL was recognized (Chang et al., 2002). Although PC is widely expressed in cell walls, calcium-dependent binding of CRP is limited to PC in bacterial and apoptotic cell walls. CRP does not bind to PC on viable cells in which the PC head groups of phospholipids are not exposed. Binding of CRP to PC is crucial for the removal of bacteria or apoptotic cells. ALP activity may be critically important in exposing PC in the cell walls and making it available for CRP binding, analogous to a role attributed to phospholipase A₂ (Hack et al., 1997). Furthermore, CRP may limit the atherogenic oxidation of LDL. For example, Rufail *et al.* found that physiological amounts of CRP strongly inhibit copper-mediated oxidation of LDL in a dose-dependent manner (Rufail et al., 2006).

Reference ranges for serum CRP concentrations in healthy premenopausal women are not well established and may vary between laboratories, not all of which use the high-sensitivity method utilized in this study. The overall mean serum CRP concentration of 6.5 mg/L in this study, measured with a high sensitivity assay, was higher than levels reported for 30- to 39-year old US women (Ford et al., 2004). This difference could be attributed to a higher incidence of obesity in our study population. It is noteworthy that, unlike Ford et al (Ford et al., 2004), we did not exclude subjects with CRP levels >10 mg/L from the analyses, because all such subjects were in the overweight and obese categories (Table 1). Because all our subjects had no complaints and had normal white blood cell counts, bacterial infections were unlikely. Serum ALP concentrations in our subjects were all also within the normal range defined for this age group (Eastman and Bixler, 1977).

Adipose tissue produces inflammatory cytokines that regulate production of many acute phase reactants including CRP, a liver protein and an important marker of inflammation. Our observations that percent body fat (and also body fat, results not shown) was the strongest independent predictor of CRP and that WBC, another important source of pro-inflammatory

cytokines, was also an independent predictor of CRP, are consistent with a regulatory role of cytokines in the production of CRP (Yudkin et al., 1999).

Total serum ALP is often elevated in non-alcoholic fatty liver disease and is used clinically as marker for this condition. However, body fat was not an independent predictor of ALP, nor was ALP an independent predictor of body fat in this defined group of premenopausal women with a wide range of BMI. Additionally, WBC, another important source of pro-inflammatory cytokines, was not an independent predictor of ALP. These results argue against a role of pro-inflammatory cytokines in influencing ALP concentrations, although both CRP and ALP are often elevated in inflammatory conditions (Kerner et al., 2005, Cheung et al., 2009). In univariate analyses, measures of adiposity, CRP, and ALP correlated with each other. However in multivariate analyses, an independent association was observed only for measures of adiposity and CRP, and for CRP and ALP, but not for ALP and obesity. These results suggest that ALP is probably important for the biological function, but not for increasing concentrations of CRP.

Some reports suggested that ALT and AST may be useful surrogate biomarkers for obesity, and these may also be elevated in non-alcoholic fatty liver disease. In this defined cohort of apparently healthy, ethnically diverse 30- to 40-year old premenopausal women, we found that CRP was the strongest positive independent predictor of all indices of excess weight (Table 4), followed by insulin and albumin. ALT and AST were additional positive independent predictors but only for waist circumference. ALP was not an independent predictor for any one of the anthropometric measurements. SHBG was a negative independent predictor of BMI, waist circumference, lean body mass, and CRP, consistent with prior studies that SHBG correlates strongly with insulin, insulin resistance, and waist circumference (Nayeem et al., 2009, Akin et al., 2009). Taken together, of the liver proteins studied, CRP appears to be more closely associated with fatty tissue as a body component, while SHBG, ALT, and AST are more closely linked to the amount of lean tissue. Insulin and albumin are associated with both fat and lean body mass.

A small study had shown that the association of CRP and ALP is gender specific and limited to females, implicating the involvement of sex steroids (Cheung et al., 2008). We showed that in a strictly defined group of premenopausal women with a wide range of body weight, estrogen, progesterone, and testosterone were not predictors of CRP and ALP. Our finding of a BMI-dependent increase in the WBC count, although within the normal range, is consistent with previous findings that the WBC count is associated with obesity and the metabolic syndrome; the mechanisms are unknown but may include fat deposition in the liver (Nakanishi et al., 2002, Dixon and O'Brien, 2006).

The major strengths of our study are (a) the inclusion of a defined group of apparently healthy young women not taking exogenous hormone preparations, (b) the measurement of CRP by an ultra-sensitive method, and (c) the measurement of ALT, AST, ALP, lipids, CRP, SHBG, insulin, and glucose on at least two separate occasions. Weaknesses of the study include the limited age range of the subjects and the cross-sectional rather than longitudinal nature of the study. We also did not separately measure liver-specific ALP isoenzyme in this study. However, prior studies investigating inflammation and liver enzymes reported total serum ALP (Kerner et al., 2005) which mostly represents liver ALP in adult humans (Young, 1967).

In summary, we have demonstrated a strong inter-relationship among circulating CRP, ALP, and body fat. Of the liver proteins we studied, CRP was the strongest independent predictor of adiposity, followed by AST, or ALT, and SHBG. Although not an independent predictor of obesity/adiposity, ALP activity may contribute importantly to the anti-inflammatory effects of CRP. Furthermore, factors produced by adipose tissue and WBC (e.g. pro-inflammatory

cytokines) may influence circulating concentrations of CRP. The critical question is whether an imbalance in the ratio of CRP to ALP, such as that may occur with obesity, may contribute to pathologic features of the metabolic syndrome.

Acknowledgments

We thank the nursing staff of the General Clinical Research Center for their assistance; the study subjects and coordinators for their dedication; Mouyong Liu for the development of the research database; and Yimei Han and Laura Ray for their biostatistical assistance. We are also very grateful to Dr. Marinel M. Ammenheuser for her critical review of the manuscript.

References

1. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894:i–xii. 1–253. [PubMed: 11234459]
2. Akin F, Bastemir M, Alkiş E, Kaptanoglu B. SHBG levels correlate with insulin resistance in postmenopausal women. *Eur J Intern Med* 2009;20:162–7. [PubMed: 19327605]
3. Bates JM, Akerlund J, Mittge E, Guillemin K. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. *Cell Host Microbe* 2007;2:371–382. [PubMed: 18078689]
4. Bentala H, Verweij WR, Huizinga-Van DV, van Loenen-Weemaes AM, Meijer DK, Poelstra K. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. *Shock* 2002;18:561–566. [PubMed: 12462566]
5. Black S, Kushner I, Samols D. C-reactive Protein. *J Biol Chem* 2004;279:48487–48490. [PubMed: 15337754]
6. Booth M, George J, Denney-Wilson E, Okely A, Hardy L, Aitken R, Dobbins T. The population prevalence of adverse concentrations and associations with adiposity of liver tests among Australian adolescents. *J Paediatr Child Health* 2008;44:686–91. [PubMed: 19054294]
7. Casey R, Newcombe J, McFadden J, Bodman-Smith KB. The acute-phase reactant C-reactive protein binds to phosphorylcholine-expressing *Neisseria meningitidis* and increases uptake by human phagocytes. *Infect Immun* 2008;76:1298–1304. [PubMed: 18195032]
8. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. *Proc Natl Acad Sci USA* 2002;99:13043–13048. [PubMed: 12244213]
9. Cheung BM, Ong KL, Cheung RV, Wong LY, Wat NM, Tam S, Leung GM, Cheng CH, Woo J, Janus ED, Lau CP, Lam TH, Lam KS. Association between plasma alkaline phosphatase and C-reactive protein in Hong Kong Chinese. *Clin Chem Lab Med* 2008;46:523–527. [PubMed: 18605934]
10. Cheung BM, Ong KL, Wong LY. Elevated serum alkaline phosphatase and peripheral arterial disease in the United States National Health and Nutrition Examination Survey 1999–2004. *Int J Cardiol* 2009;135:156–161. [PubMed: 18572267]
11. Coussens LM, Werb Z. Inflammation and cancer. *Nature* 2002;420:860–867. [PubMed: 12490959]
12. de Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. *Cardiovasc Pathol* 2007;16:14–21. [PubMed: 17218210]
13. Dixon J, O'Brien P. Obesity and the white blood cell count: changes with sustained weight loss. *Obes Surg* 2006;16:251–7. [PubMed: 16545154]
14. Eastman JR, Bixler D. Serum alkaline phosphatase: normal values by sex and age. *Clin Chem* 1977;23:1769–1770. [PubMed: 890920]
15. Florez H, Castillo-Florez S, Mendez A, Casanova-Romero P, Larreal-Urdaneta C, Lee D, Goldberg R. C-reactive protein is elevated in obese patients with the metabolic syndrome. *Diabetes Res Clin Pract* 2006;71:92–100. [PubMed: 16002176]
16. Ford ES, Giles WH, Mokdad AH, Myers GL. Distribution and correlates of C-reactive protein concentrations among adult US women. *Clin Chem* 2004;50:574–581. [PubMed: 14709450]

17. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. *Diabetes* 2002;51:1596–1600. [PubMed: 11978661]
18. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. *CMAJ* 2005;172:367–379. [PubMed: 15684121]
19. Gockel I, Dirksen K, Messow CM, Junginger T. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. *World J Gastroenterol* 2006;12:3746–3750. [PubMed: 16773693]
20. Hack CE, Wolbink GJ, Schalkwijk C, Speijer H, Hermens WT, van Den BH. A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. *Immunol Today* 1997;18:111–115. [PubMed: 9078682]
21. Hotamisligil G. Inflammation and metabolic disorders. *Nature* 2006;444:860–7. [PubMed: 17167474]
22. Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, Levy Y, Brook GJ, Aronson D. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2005;25:193–197. [PubMed: 15499043]
23. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. *Clin Immunol* 2005;117:104–111. [PubMed: 16214080]
24. McComb, RB.; Bowers, GN.; Posen, S. Alkaline Phosphatase. New York: Plenum Press; 1979.
25. McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Pollak M, Tao Y, Helzlsouer KJ. C-reactive protein concentrations and subsequent ovarian cancer risk. *Obstet Gynecol* 2007;109:933–941. [PubMed: 17400857]
26. Nakanishi N, Sato M, Shirai K, Nakajima K, Murakami S, Takatorige T, Suzuki K, Tatara K. Associations between white blood cell count and features of the metabolic syndrome in Japanese male office workers. *Ind Health* 2002;40:273–7. [PubMed: 12141376]
27. Nayeem F, Nagamani M, Anderson K, Huang Y, Grady J, Lu L. Dietary beta-tocopherol and linoleic acid, serum insulin, and waist circumference predict circulating sex hormone-binding globulin in premenopausal women. *J Nutr* 2009;139:1135–42. [PubMed: 19339706]
28. Polterauer S, Grimm C, Tempfer C, Sliutz G, Speiser P, Reinthaller A, Hefler LA. C-reactive protein is a prognostic parameter in patients with cervical cancer. *Gynecol Oncol* 2007;107:114–117. [PubMed: 17617445]
29. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. *Nutr Rev* 2007;65:S253–S259. [PubMed: 18240558]
30. Rufail ML, Ramage SC, Van AR. C-reactive protein inhibits in vitro oxidation of low-density lipoprotein. *FEBS Lett* 2006;580:5155–5160. [PubMed: 16962105]
31. Tillett WS, Francis JT. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. *J Exp Med* 1930;52:561–585. [PubMed: 19869788]
32. Verweij WR, Bentala H, Huizinga-Van DV, Miek VLW, Kooi K, Meijer DK, Poelstra K. Protection against an *Escherichia coli*-induced sepsis by alkaline phosphatase in mice. *Shock* 2004;22:174–179. [PubMed: 15257092]
33. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. *JAMA* 1999;282:2131–2135. [PubMed: 10591334]
34. Weiser JN, Goldberg JB, Pan N, Wilson L, Virji M. The phosphorylcholine epitope undergoes phase variation on a 43-kilodalton protein in *Pseudomonas aeruginosa* and on pili of *Neisseria meningitidis* and *Neisseria gonorrhoeae*. *Infect Immun* 1998;66:4263–4267. [PubMed: 9712776]
35. Young JM. Origins of serum alkaline phosphatase. *J Clin Pathol* 1967;20:647–653. [PubMed: 5628857]
36. Yudkin J, Stehouwer C, Emeis J, Coppack S. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? *Arterioscler Thromb Vasc Biol* 1999;19:972–8. [PubMed: 10195925]
37. Zambon A, Pauletto P, Crepaldi G. Review article: the metabolic syndrome—a chronic cardiovascular inflammatory condition. *Aliment Pharmacol Ther* 2005;22 2:20–23. [PubMed: 16225466]

38. Zhang D, Jiang S, Rzewnicki D, Samols D, Kushner I. The effect of interleukin-1 on C-reactive protein expression in Hep3B cells is exerted at the transcriptional level. *Biochem J* 1995;310(Pt 1): 143–8. [PubMed: 7646436]

Table 1
General characteristics of the study subjects (30-40 year old premenopausal women from within an 80 km radius of Galveston, TX, n=233 unless otherwise indicated)

	<i>All</i>	<i>Normal-weight^a</i> (18.5 - 24.9) kg/m ²	<i>Overweight</i> (25 - 29.9) kg/m ²	<i>Obese</i> ≥30 kg/m ²
	n=233	n=69	n=78	n=86
<i>Demographic and Anthropometric</i>				
BMI (kg/m ²)	28.4 (5.5) ^b	22.3 (1.7)	27.5 (1.5) [‡]	34.2 (3.5) ^{‡¶}
Age (y)	36.3 (2.7)	36.1 (2.4)	36.3 (2.6)	36.4 (3.0)
Body weight (kg)	74.4 (14.5)	59.9 (6.6)	71.7 (6.7) [‡]	88.4 (11.1) ^{‡¶}
Height (cm)	161.9 (6.7)	163.8 (6.2)	161.5 (6.8)	160.6 (6.8) [§]
Waist circumference (cm)	87.6 (11.4)	75.8 (5.9)	85.5 (5.5) [‡]	98.9 (7.4) ^{‡¶}
Hip circumference (cm)	109.2 (12.0)	97.7 (6.1)	107.1 (5.0) [‡]	120.3 (10.3) ^{‡¶}
Waist to hip ratio	0.80 (0.06)	0.78 (0.05)	0.80 (0.05) [‡]	0.83 (0.07) [¶]
Lean body mass (kg)	46.4 (6.2)	42.0 (4.6)	45.3 (4.5) [‡]	50.9 (5.6) ^{‡¶}
Fat body mass (kg)	28.2 (9.8)	18.2 (4.2)	26.6 (4.2) [‡]	37.7 (7.7) ^{‡¶}
Percent body fat	36.9 (6.7)	30.1 (5.2)	37.0 (4.0) [‡]	42.3 (4.5) ^{‡¶}
<i>Race/Ethnicity</i>				
Non-Hispanic White, n (%)	119 (51.1)	46 (66.7)	38 (48.7)	35 (40.7)
Hispanic, n (%)	70 (30.0)	12 (17.4)	23 (29.5)	35 (40.7)
African American, n (%)	33 (14.2)	6 (8.7)	13 (16.7)	14 (16.3)
Other ^c , n (%)	11 (4.7)	5 (7.2)	4 (5.2)	2 (2.3)
<i>Reproductive</i>				
Parity				
Yes, n (%)	203 (87)	60 (87.0)	66 (84.6)	77 (90.6)
No, n (%)	29 ^d (13)	9 (13.0)	12 (15.4)	8 ^d (9.4)
Age of menarche (y), n=227	12.6 (1.5)	12.8 (1.5)	12.7 (1.5)	12.5 (1.6)
Number of complete pregnancies	2.2 (1.3)	2.1 (1.3)	2.2 (1.3)	2.2 (1.4)
<i>Blood Chemistry (fasting)</i>				
Glucose (mmol/l)	4.8 (0.6)	4.6 (0.3)	4.7 (0.4)	5.0 (0.8) ^{‡§}
Triglycerides (mmol/l)	1.2 (0.7)	0.8 (0.3)	1.1 (0.6)	1.4 (0.8) ^{‡¶}
Cholesterol (mmol/l)	4.7 (0.8)	4.5 (0.8)	4.7 (0.8)	4.8 (0.8)
HDL-C (mmol/l)	1.4 (0.3)	1.6 (0.3)	1.4 (0.3) [‡]	1.3 (0.2) [‡]
ALP (u/l)	70.3 (16.0)	63.4 (15.7)	68.3 (13.7)	77.3 (15.7) ^{‡¶}
ALT (u/l)	3.2 (0.3)	3.2 (0.2)	3.2 (0.3)	3.3 (0.3)
AST (u/l)	20.8 (4.9)	20.8 (4.5)	21.3 (5.1)	20.3 (5.0)
Albumin (g/l)	40.9 (3.2)	42.2 (2.8)	40.9 (3.5)	39.7 (2.8) [‡]
WBC count (×10 ³ /μl)	6.2 (1.5)	5.4 (1.1)	6.1 (1.4)	6.9 (1.6) ^{‡¶}

	<i>All</i>	<i>Normal-weight^a</i> (18.5 - 24.9) kg/m ²	<i>Overweight</i> (25 - 29.9) kg/m ²	<i>Obese</i> ≥30 kg/m ²
	n=233	n=69	n=78	n=86
<i>Hormones (fasting)</i>				
CRP (mg/l)	6.5 (6.9)	1.8 (1.9)	5.4 (4.4) [†]	11.2 (8.2) ^{‡¶}
SHBG (nmol/l)	101.0 (39.4)	126.2 (39.1)	97.9 (31.3) [‡]	83.5 (35.8) [‡]
Insulin (pmol/l)	80.5 (53.8)	43.5 (27.2)	70.6 (45.5) [†]	119.2 (52.1) ^{‡¶}
Testosterone (pmol/l)	25.8 (12.2)	24.1 (13.0)	24.9 (10.0)	28.1 (13.1)
17β-Estradiol (pmol/l), n=201	293.2 (136.3)	281.7 (99.4)	302.9 (149.1)	294.3 (152.5)
Progesterone (nmol/l)	33.8 (16.2)	34.1 (16.3)	36.6 (15.2)	31.0 (16.8)

Abbreviations: ALT, alanine amino transferase; ALP, alkaline phosphatase; AST, aspartate amino transferase; BMI, body mass index; CRP, C-reactive protein; HDL-C, high density lipoprotein-cholesterol; SHBG, sex hormone binding globulin, WBC, white blood cells;

^aBased on WHO BMI criteria,

^bMean (SD),

^cOther=non-specified, Asian, and American Indian ethnicities combined,

^dmissing frequency=1;

[†]P <0.05 vs. normal-weight group,

[‡]P<0.005 vs. normal-weight group,

[§]P<0.05 vs. overweight group,

[¶]P<0.005 vs. overweight group.

Table 2
Pearson correlation coefficients for log CRP and serum ALP with various predictor variables among study subjects, n=233 unless otherwise indicated

	<i>LogCRP</i>		<i>ALP</i>	
	<i>r</i>	<i>P value</i>	<i>r</i>	<i>P value</i>
<i>Demographic and Anthropometrics</i>				
Height	- 0.21	0.001	- 0.17	0.01
Weight	0.58	<0.0001	0.31	<0.0001
BMI	0.67	<0.0001	0.39	<0.0001
Lean body mass	0.29	<0.0001	0.14	0.04
Fat body mass	0.66	<0.0001	0.38	<0.0001
Percent body fat	0.70	<0.0001	0.39	<0.0001
Waist circumference	0.65	<0.0001	0.34	<0.0001
Hip circumference	0.57	<0.0001	0.30	<0.0001
Age of menarche	- 0.15	0.02	-0.05	n.s
<i>Hormones and Blood Chemistry</i>				
Insulin	0.49	<0.0001	0.36	<0.0001
SHBG	- 0.42	<0.0001	- 0.19	0.004
Testosterone	0.10	n.s	0.08	n.s
17 β -Estradiol, n=201	0.11	n.s	- 0.01	n.s
Progesterone	- 0.06	n.s	-0.05	n.s
Cholesterol	0.12	n.s	0.06	n.s
HDL-C	- 0.41	<0.0001	- 0.17	0.01
Triglycerides	0.34	<0.0001	0.19	0.004
Glucose	0.25	<0.0001	0.19	0.004
Albumin	-0.24	0.0003	- 0.17	0.01
ALP	0.44	<0.0001	1.00	
Log ALT	0.1	n.s	0.11	n.s
Log AST	- 0.04	n.s	0.05	n.s
WBC count	0.45	<0.0001	0.29	<0.0001

Abbreviations: ALT, alanine amino transferase; ALP, alkaline phosphatase; AST, aspartate amino transferase; BMI, body mass index; CRP, C-reactive protein; HDL-C, high density lipoprotein-cholesterol; SHBG, sex hormone binding globulin, WBC, white blood cells

Table 3
Multiple OLS regression models with log CRP and ALP as the dependent variables in study subjects, (n=233)

	CRP	ALP
Percent body fat	0.49 (<0.0001) [§]	0.12 (0.18)
Log CRP (mg/l)	.	0.27 (0.003)
ALP (u/l)	0.15 (0.003)	.
Log ALT (u/l)	0.03 (0.54)	0.05 (0.50)
Log AST (u/l)	0.002 (0.97)	0.06 (0.44)
SHBG (nmol/l)	-0.12 (0.02)	0.04 (0.54)
Insulin (pmol/l)	0.05 (0.41)	0.18 (0.03)
Glucose (mmol/l)	-0.02 (0.61)	0.02 (0.76)
Triglycerides (mmol/l)	0.04 (0.49)	-0.03 (0.66)
HDL-C (mmol/l)	-0.07 (0.20)	0.06 (0.44)
WBC count ($\times 10^3/\mu\text{l}$)	0.15 (0.004)	0.10 (0.15)
Model R ²	0.59	0.25

Abbreviations: ALT, alanine amino transferase; ALP, alkaline phosphatase; AST, aspartate amino transferase; BMI, body mass index; CRP, C-reactive protein; HDL-C, high density lipoprotein-cholesterol; SHBG, sex hormone binding globulin; WBC, white blood cells,

[§]Standardized β -coefficients (*P* value)

Table 4
Multiple OLS regression models showing associations between various measures of adiposity and predictor variables in study subjects, (n=233)

	BMI	Waist circumference	Percent body fat	Lean body mass
Log CRP (mg/l)	0.39 (<0.0001) [§]	0.36 (<0.0001)	0.55 (<0.0001)	0.09 (0.26)
ALP (u/l)	0.04 (0.42)	-0.02 (0.66)	0.06 (0.27)	-0.05 (0.40)
Log ALT (u/l)	0.09 (0.09)	0.17 (0.004)	-0.02 (0.77)	0.19 (0.02)
Log AST (u/l)	-0.08(0.11)	-0.14 (0.01)	-0.07 (0.22)	-0.09 (0.25)
SHBG (nmol/l)	-0.1 (0.04)	-0.12 (0.02)	-0.06 (0.26)	-0.13 (0.07)
Insulin (pmol/l)	0.26 (<0.0001)	0.27 (<0.0001)	0.14 (0.02)	0.21 (0.007)
Albumin (g/l)	-0.21 (<0.0001)	-0.15 (0.001)	-0.14 (0.004)	-0.13 (0.03)
WBC count (×10 ³ /μl)	0.04 (0.38)	0.1 (0.04)	0.002 (0.97)	0.04 (0.61)
Model R ²	0.60	0.58	0.55	0.20

Abbreviations: ALT, alanine amino transferase; ALP, alkaline phosphatase; AST, aspartate amino transferase; BMI, body mass index; CRP, C-reactive protein; SHBG, sex hormone binding globulin; WBC, white blood cells,

[§]Standardized β -coefficients (*P* value).